RECRUITING

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Description

The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.

Conditions

ObesityOverweightType 2 Diabetes
Talk to us

Related Conditions:

ObesityOverweightType 2 Diabetes

Study Overview

On this page

Study Details

Study overview

The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO. Participation in the study will last about 18 months.

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Condition
Obesity
Intervention / Treatment

-

Contacts and Locations

Tucson

Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson, Arizona, United States, 85741

San Ramon

Norcal Endocrinology & Internal Medicine, San Ramon, California, United States, 94583

Santa Ana

Southern California Clinical Research, Santa Ana, California, United States, 92701

Thousand Oaks

Care Access - Thousand Oaks, Thousand Oaks, California, United States, 91360

DeLand

Accel Research Sites - DeLand Clinical Research Unit, DeLand, Florida, United States, 32720

Fort Lauderdale

Innovation Medical Research Center - Fort Lauderdale, Fort Lauderdale, Florida, United States, 33316

Hollywood

Encore Medical Research, Hollywood, Florida, United States, 33024

Ocoee

West Orange Endocrinology P.A., Ocoee, Florida, United States, 34761

Tampa

Care Access - Tampa, Tampa, Florida, United States, 33625

Decatur

Accel Research Sites - NeuroStudies Clinical Research Unit, Decatur, Georgia, United States, 30030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have body mass index (BMI) ≥25 kilograms per square meter (kg/m2) at screening
  • * Have type 2 diabetes
  • * Have hemoglobin A1c (HbA1c) ≥7% and ≤10% at screening
  • * Have a history of at least one unsuccessful dietary effort to lose body weight
  • * Have type 1 diabetes
  • * Have an unstable body weight within 90 days prior to screening
  • * Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening
  • * Have acute or chronic hepatitis or pancreatitis
  • * Are taking other medications or alternative remedies to manage weight loss

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eli Lilly and Company,

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

2027-08